Physiogenex provides preclinical CRO services and expertise with a 15-year expertise in evaluating drugs targeting obesity/diabetes, NASH/fibrosis, diabetic nephropathy & cardiovascular complications, dyslipidemia/atherosclerosis.
See our most popular models:
- ultra-fast 3-week NASH mouse model
- Our unique human-like NASH hamster model validated with OCA and elafibranor
- MCD mouse and CCl4 or TAA liver fibrosis models
- Our original DIO rat model fed a free-choice diet
- DIO mouse model for radioactive clamp experiments
- Innovative and awarded diabetic nephropathy mouse and rat models
- Atherosclerosis models
All our models are provided with benchmarks and validated in vivo experiments, biochemical assays and histology analysis/NAS scoring. Frozen/fixed biological samples from our models can be shipped to test your biomarkers and therapeutic target.
Our services to evaluate your drugs targeting
LIVER DISEASES 
NAFLD
Hepatic steatosis
to fibrosis
Animal models
from basic to predictive
in-house models
from basic to predictive
in-house models
Experimental platform
From gold-standard to innovative assays
From gold-standard to innovative assays
Scientific expertise and translational vision